Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479563 | 0.86 | PARP1 (0.51) | MAPK1LMNAKDM4ETSHRRCE1 | |
| SCHEMBL6480598 | 0.82 | PARP1 (0.48) | MAPK1LMNAKDM4ETSHRRCE1 | |
| SCHEMBL6488700 | 0.82 | GAA (0.47) | MAPK1LMNAKDM4ETSHRRCE1 | |
| SCHEMBL6480584 | 0.81 | DRD4 (0.48) | MAPK1LMNAKDM4ETSHRKMT2A | |
| SCHEMBL6481689 | 0.79 | KDM4E (0.43) | MAPK1LMNAKDM4ETSHRRCE1 | |
| SCHEMBL6479250 | 0.79 | ALDH1A1 (0.52) | MAPK1LMNAKDM4ETSHRPOLB | |
| SCHEMBL6230408 | 0.78 | SLC6A7 (0.60) | SLC6A7KDM4ENAMPTPOLBKMT2A | |
| SCHEMBL6481851 | 0.77 | KMT2A (0.59) | MAPK1LMNAKDM4ETSHRKMT2A | |
| SCHEMBL23244334 | 0.74 | ME2 (0.58) | MAPK1LMNAKDM4ETSHRRCE1 | |
| SCHEMBL29577260 | 0.74 | ME2 (0.58) | MAPK1LMNAKDM4ETSHRRCE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009809-A1 | Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors | ZENTARIS GMBH (DE) | 2005-01-13 | — | — | US | claimed |
| WO-2005007643-A1 | NOVEL ACRIDINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | ZENTARIS GMBH (DE) | 2005-01-27 | — | — | WO | disclosed |
| US-20050009809-A1 | Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors | ZENTARIS GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009809-A1 | Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors | PKD1, MDH2, MSH2 | SLC6A7 3499/4885MAPK1 575/4885LMNA 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.